Hologic Inc. (NASDAQ:HOLX) – Equities research analysts at Leerink Swann issued their Q1 2017 earnings per share estimates for shares of Hologic in a note issued to investors on Thursday. Leerink Swann analyst R. Newitter expects that the brokerage will post earnings of $0.51 per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $46.00 target price on the stock. Leerink Swann also issued estimates for Hologic’s Q2 2017 earnings at $0.53 EPS, Q3 2017 earnings at $0.55 EPS, Q4 2017 earnings at $0.56 EPS, FY2018 earnings at $2.37 EPS and FY2019 earnings at $2.66 EPS.
Several other analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a research report on Wednesday, September 28th. Barclays PLC upgraded shares of Hologic from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $42.00 to $44.00 in a research report on Friday, September 23rd. Piper Jaffray Cos. set a $44.00 target price on shares of Hologic and gave the company a “hold” rating in a research report on Sunday, August 28th. RBC Capital Markets reiterated a “sector perform” rating and set a $39.00 target price (up from $37.00) on shares of Hologic in a research report on Monday, August 1st. Finally, Royal Bank Of Canada boosted their price target on shares of Hologic from $37.00 to $39.00 and gave the company a “sector perform” rating in a research report on Monday, August 1st. Six investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Hologic has a consensus rating of “Buy” and an average price target of $42.71.
Hologic (NASDAQ:HOLX) opened at 39.15 on Monday. Hologic has a 1-year low of $31.84 and a 1-year high of $41.66. The firm has a market cap of $10.86 billion, a price-to-earnings ratio of 43.16 and a beta of 1.00. The company’s 50 day moving average is $38.33 and its 200-day moving average is $36.13.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 27th. The company reported $0.51 EPS for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.03. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The business had revenue of $717.40 million for the quarter, compared to analyst estimates of $703.66 million. During the same quarter last year, the business earned $0.43 earnings per share. The business’s revenue for the quarter was up 3.4% on a year-over-year basis.
In other Hologic news, Director Nancy Leaming sold 6,221 shares of the company’s stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $36.04, for a total value of $224,204.84. Following the completion of the sale, the director now owns 55,053 shares of the company’s stock, valued at $1,984,110.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.84% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Hologic by 8.1% in the second quarter. Vanguard Group Inc. now owns 26,537,173 shares of the company’s stock valued at $918,185,000 after buying an additional 1,992,898 shares during the last quarter. State Street Corp increased its stake in shares of Hologic by 2.8% in the second quarter. State Street Corp now owns 10,579,925 shares of the company’s stock valued at $366,073,000 after buying an additional 284,089 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in shares of Hologic by 6.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 7,195,938 shares of the company’s stock valued at $248,979,000 after buying an additional 441,354 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of Hologic by 37.5% in the second quarter. Prudential Financial Inc. now owns 3,613,781 shares of the company’s stock valued at $125,036,000 after buying an additional 986,320 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Hologic by 56.1% in the second quarter. AQR Capital Management LLC now owns 2,983,023 shares of the company’s stock valued at $103,212,000 after buying an additional 1,072,100 shares during the last quarter. 94.51% of the stock is owned by hedge funds and other institutional investors.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.